Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AMRI | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AMRI

Cedarburg business boosts large scale manufacturing revenue

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AMRI

2Q Revenues: $68.2 million (+15%)

2Q Earnings: $3.7 million (loss of $2.5 million in 2Q13)

YTD Revenues: $127.5 million (+7%)

YTD Earnings: $7.2 million (+90%)

Comments: Contract revenue was $61.5 million, up 21% driven by increased capacity utilization and the addition of Cedarburg Pharmaceuticals. Discovery Services and Development/Small Scale Manufacturing (DDS) contract revenue in the quarter was flat at $19.5 million. Large Scale Manufacturing (LSM) contract revenue was $42.0 million, up 34%, which includes $5.5 million of revenues from the Cedarburg business. Royalty revenue in the quarter was $6.7 million, down 21%. Royalties include Allegra products, which continue to face generic competition, as well as $2.5 million from the net sales of certain amphetamine salts sold by Actavis. The company recently acquired Oso Biopharmaceuticals Manufacturing in July 2014, expanding its contract manufacturing capabilities to include commercial scale, complex injectable drug product.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters